Table 1.
Cohort characteristics. Age, gender and dose intervals for each vaccine combination
| Dose 1 | AZD | BBIBP | mRNA-1273 | Sput-26 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose 2 | Overall, n = 497 | Ad5, n = 20 | AZD, n = 41 | BBIBP, n = 25 | mRNA-1273, n = 32 | Sput-26, n = 29 | AZD, n = 25 | BBIBP, n = 40 | mRNA-1273, n = 30 | Sput-26, n = 33 | mRNA-1273, n = 20 | Ad5, n = 29 | AZD, n = 36 | BBIBP, n = 34 | mRNA-1273, n = 42 | Sput-26, n = 25 | Sput-5, n = 36 | |
| Age | 41.8 ± 15.6 | 32.6 ± 9.4 | 50.9 ± 12.9 | 39.1 ± 10.4 | 43.4 ± 10.9 | 46.2 ± 11.5 | 26.2 ± 13.5 | 29.1 ± 13.0 | 26.8 ± 11.8 | 32.4 ± 14.2 | 26.9 ± 10.3 | 39.2 ± 14.8 | 53.2 ± 11.0 | 52.1 ± 12.3 | 54.7±9.2 | 47.7 ±10.8 | 49.5 ±13.1 | |
| Gender | F | 252 (51%) | 10 (50%) | 21 (51%) | 12 (48%) | 14 (44%) | 14 (48%) | 13 (52%) | 19 (48%) | 16 (53%) | 18 (55%) | 11 (55%) | 20 (69%) | 16 (44%) | 13 (38%) | 23 (55%) | 12 (48%) | 20 (56%) |
| M | 245 (49%) | 10 (50%) | 20 (49%) | 13 (52%) | 18 (56%) | 15 (52%) | 12 (48%) | 21 (52%) | 14 (47%) | 15 (45%) | 9 (45%) | 9 (31%) | 20 (56%) | 21 (62%) | 19 (45%) | 13 (52%) | 16 (44%) | |
| T1 (days after dose 1) | 64.8 ± 23.7 | 73.6 ± 9.6 | 65.7 ± 6.9 | 65.2 ± 3.1 | 66.9 ± 16.9 | 62.4 ± 7.7 | 33.3 ± 3.1 | 45.8 ± 17.6 | 35.1 ± 4.7 | 38.9 ± 12.9 | 32.9 ± 2.8 | 79.0 ± 12.7 | 82.9 ± 18.9 | 85.0 ± 27.0 | 84.8 ± 17.3 | 82.4 ± 8.0 | 83.6 ± 18.4 | |
| T2 (days after dose 2) | 14.3 ± 1.5 (n = 437) | 14.2 ± 0.5 (n = 18) | 14.2 ± 0.6 (n = 35) | 14.3 ± 0.7 (n = 23) | 14.5 ± 2.6 (n = 29) | 14.1 ± 0.4 (n = 28) | 14.4 ± 0.8 (n = 22) | 14.8 ± 1.8 (n = 26) | 14.2 ± 0.7 (n = 27) | 15.1 ± 2.7 (n = 27) | 14.1 ± 0.3 (n = 14) | 14.3 ± 0.7 (n = 27) | 14.7±3.3 (n = 33) | 14.1±0.6 (n = 34) | 14.0± 0.0 (n = 39) | 14.2± 0.7 (n = 23) | 14.1 ± 0.6 (n = 32 | |
| T3 (days after dose 2) | 28.4 ± 1.2 (n = 420) | 29.3 ± 0.9 (n = 19) | 28.6 ± 1.6 (n = 30) | 28.4 ± 0.9 (n = 20) | 28.1 ± 0.8 (n = 27) | 28.2 ± 0.9 (n = 27) | 28.1 ± 0.3 (n = 22) | 28.8 ± 1.6 (n = 26) | 28.0 ± 0.0 (n = 23) | 28.2 ± 1.4 (n = 26) | 28.7 ± 1.4 (n = 13) | 29.2 ± 1.6 (n = 26) | 28.2 ± 0.9 (n = 31) | 28.5 ± 1.7 (n = 34) | 28.1 ± 0.3 (n = 38) | 28.0 ± 0.0 (n = 23) | 28.2 ± 1.1 (n = 35) | |
Mean ± s.d. number of days and standard deviation after dose 1 or dose 2 were calculated from a subset of the total participants, as indicated below each mean.